



EGFR Resisters RESEARCH SUMMIT

An Academic Research Summit Focusing on the
Advancement of EGFRm Treatment Paradigms
through Meaningful Collaboration between
Physician Scientist Investigators and Patients


www.egfrsummit.com

Follow us on Twitter @EGFRSummit

NEWSLETTER

EGFR RESISTERS RESEARCH SUMMIT OVERVIEW

The second annual EGFR Resisters Research Summit convened November 12-14, 2020 in a virtual format due to the COVID-19 pandemic.



Twenty-one Young Investigators, nine Expert Faculty Judge Mentors, and three patient advocates kicked off #EGFRSummit20 in a Welcome Zoom entitled, "2020: It's Been a Year," a fast-paced debrief of how the COVID disruption has impacted clinical research in lung cancer and the EGFR-focused space. This was followed by EGFR Resisters founding members, Ivy Elkins, Jill Feldman, and Dr. Ildiko Medve, providing an update on the expanding reach of the EGFR Resisters and the impact of their funded projects. The presentation concluded with a video clip from The Today Show, which showcased Jill Feldman's personal journey with lung cancer. Young Investigators invited to present in Breakout Sessions wrapped up Thursday evening by sharing their data in groups of 7-10 with three Faculty Judge Mentors, a patient advocate, and several peers. These intimate working groups illustrated the overarching purpose of the EGFR Summit: to advance the EGFRm treatment paradigm through meaningful collaboration between physician scientist investigators and patients.

We opened Friday with a mentoring session on clinical trial design, led by new Judge Mentor Dr. Suresh Ramalingam. Young Investigators presented a host of General Session presentations throughout the day, broken up by EGFR Squads and mentoring sessions on grant writing and publishing tips, presented by Dr. John Heymach and Dr. Christine Lovly, respectively.

EGFR Squads were added in 2020 as a small group component wherein each Judge Mentor could meet several times over the weekend with 2-3 Young Investigators as a check-in to debrief the science presented. Each squad was strategically designed to connect researchers with similar expertise/interests, but who were from different institutions and geographical areas. The idea was to cultivate new mentor-mentee and peer collaborations and we have found this has been sustained since the November meeting for many participants.

Saturday was composed of additional Mentoring Moment sessions on best practices for social media use, leadership and mentoring, and a Q&A with the full faculty panel. The meeting concluded with an awards session, where nine Young Investigators were honored for their exemplary work.



"[The] patient advocacy component was very strong and moving in this conference."

ABOUT THE EGFR RESISTERS PATIENT ADVOCACY GROUP

Established in 2017 by seven original members—who drew on their experience as patients, survivors, caregivers, and healthcare providers—the EGFR Resisters represent a grassroots, patient-driven community dedicated exclusively to changing EGFR-mutated lung cancer into a chronic, manageable disease. With more than 2,600 members from more than 75 countries across the globe, the EGFR Resisters have become a well-established and widely-known oncogene driver group that is galvanizing research efforts in meaningful and unique ways, including data gathering efforts such as Project PRIORITY and the EGFR Resisters Research Summit, which is a Young Investigator Forum that brings together established experts with the next generation of lung cancer researchers. CEC Oncology is excited and honored to partner with the EGFR Resisters in organizing and delivering the Summit each year.



Presented by the EGFR Resisters
and Creative Educational Concepts, Inc.

Supported by an independent
educational grant from AstraZeneca.

 **2020 EGFR RESISTERS DISTINGUISHED YOUNG INVESTIGATOR
GRAND PRIZE—\$10,000**



Joseph Chan, MD, PhD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center

Uncovering Molecular Drivers of Neuroendocrine Plasticity in Patients with Small Cell Lung Cancer Transformation at Single-cell Level

"The EGFR Resisters Summit was a fantastic, eye-opening experience. It was both inspiring and humbling to meet luminary giants in the field, learn about all the new, innovative research that my colleagues are conducting, and hear firsthand the experiences of patients and how they hope that our research may impact their lives. The experience really encouraged me to continue following this career path of a physician scientist."

"I plan to use this award on computing expenses and related equipment, as well as any sequencing expenses not covered by other grants."

 **1ST RUNNER-UP**



Kristen A. Marrone, MD
Assistant Professor
Johns Hopkins University School of Medicine

Harnessing EGFR-specific Immune Responses to Optimize Treatment

"This retreat was invaluable to me, as I was able to present my research and discuss it with both peers and leaders in the field of EGFR-specific therapies. It has already led to amazing collaborations and has widened my mentoring network. It also helped me think about my career trajectory and recentered my focus on how best to be involved in EGFR-specific research as my career develops."

"I plan to use the award money to fund my ongoing translational research efforts to evaluate the anti-tumor immune response in patients whose tumor harbors an EGFR mutation in the context of immunotherapy treatments, as well as participate in presentation of these findings."

 **2ND RUNNER-UP**



Andrew Piper-Vallillo, MD
Fellow
Massachusetts General Hospital
Beth Israel Deaconess Medical Center

***High-dose Osimertinib for CNS Progression in EGFR+ NSCLC:
A Multi-Institutional Experience***

"Attending and presenting at the EGFR Resisters conference was a highly valuable professional development opportunity. I learned a great deal through feedback on my presentation in the lead-up to the conference and then through real-time critique by the expert panel. Moreover, the conference was an incredible opportunity to meet with and learn from clinician-scientists spanning the basic-clinical research spectrum and at various phases in their careers (from young investigators to well-established PIs). I came away with new insights into presenting, grant/scientific writing, academic advancement, and even how to curate my Twitter presence. Overall, a tremendously positive experience."

"I plan to use this grant award to support my ongoing research efforts in EGFR-mutant NSCLC, specifically to fund conference registration fees and purchase research-computing software/equipment."

3RD RUNNER-UP



Julia Rotow, MD
Clinical Instructor
Dana-Farber Cancer Institute

Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-small Cell Lung Cancer (NSCLC)

"As an early career investigator in thoracic oncology, with a focus on translational and clinical research in EGFR-mutated lung cancer, opportunities like the summit to meet with the EGFR research community are critical. It is so important to see the work that is going on across this country on this topic, meet with other upcoming investigators in the space with whom I hope to collaborate in the future, and to learn from the experience of more senior investigators who have successfully contributed to the field. Building these networks helps to lay the groundwork for future studies, which can often be done most effectively by collaborating across institutions. Particularly during the COVID pandemic, when opportunities to meet with and learn from others in the field are limited, these virtual meetings can have a large impact. I look forward to working with those I met, both in the academic and patient advocacy communities, going forward."

"I will apply the award funds from the EGFR Resisters Summit toward generating initial supporting data for future funding applications."

HONORABLE MENTIONS



Fernando de Miguel, PhD
Postdoctoral Associate
Yale University

The Chromatin Remodeling Factor SMARCA4 Regulates Proliferation and Oxidative Stress in Osimertinib Resistant EGFR-mutant Lung Adenocarcinoma

"I had a lot of great feedback about my career and my science. I also made very good connections with great scientists and colleagues working in the same field that I am in."

"I will purchase some reagents for my experiments."



Yunkai Zhang, PhD
Research Fellow
Vanderbilt University Medical Center

Identify, Characterize, and Develop Strategies to Combat Drug-tolerant Persister Cells (DTPCs) before the Development of Acquired TKI Resistance in EGFR-mutant Lung Cancer

"First, participating in the Summit let me connect with other young investigators who are at a similar stage as I am, which is super beneficial to learn from each other, share updated information, etc. These independent early-stage connections are important for my career development. Second, I have received wonderful advices/tips/lessons from developed investigators, and these will definitely guide me along the professional development. Third, I have also heard inspiring and encouraging stories from the patient advocates, which (assures me of) the impact of research that we are all conducting."

"I am planning to use the award to purchase some computational resources (RAMs, etc.), which will allow me to analyze more scRNAseq datasets in a more efficient manner."



Noura Choudhury, MD
Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center

A Phase II Trial of Combination Amivantamab and Lazertinib in Metastatic EGFR-mutated Lung Adenocarcinoma with CNS Progression Using Integrated CSF cfDNA Analysis

"Participating in the EGFR Resisters Research Summit allowed me to get early feedback on my proposed trial, meet with experts in the field of EGFR-mutant lung cancer, and form future professional connections. [It also] gave me the opportunity to practice and acquire professional skills in presentation and oral delivery."

"I will use the grant money toward future travel to an academic conference, once travel is allowed again in a post-COVID-19 world."



Jaime Schneider, MD, PhD
Medical Oncology Fellow
Massachusetts General Hospital
Dana Farber Cancer Institute

Role of Metabolic Reprogramming in Mediating Resistance in Oncogene-driven Non-small Cell Lung Cancer

"The major ways that the EGFR summit has impacted my professional development include: 1) the educational experience of hearing about different avenues of research being pursued in EGFR-mutant lung cancer; and 2) being able to (virtually) meet various faculty throughout the country, thus facilitating new connections and potential collaborations."

"I plan to use the award to directly support research efforts, including purchasing of lab reagents, lab equipment, and toward using core services at my institution."



Maya White, MD, MS
Fellow
Stanford University

Survival Outcomes in Lung Cancer Patients with Actionable Mutations Admitted to Intensive Care Units

"I was able to make connections with other researchers with similar interest—because of this conference, I am already involved in a multi-institution project!"

"[I plan to use the award for] journal publication fees."



 2020 EGFR RESISTERS RESEARCH SUMMIT FACULTY



Joshua Bauml, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania



Joel Neal, MD, PhD

Associate Professor of Medicine (Oncology)
Stanford University Medical Center
Palo Alto, California



Ivy Elkins, MBA

Founding Member, EGFR Resisters
EGFR+ NSCLC since 2014
Buffalo Grove, Illinois



Zofia Piotrowska, MD, MHS

Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts



Jill Feldman, MA

Founding Member, EGFR Resisters
EGFR+ NSCLC since 2009
Deerfield, Illinois



Suresh S. Ramalingam, MD, FASCO

Deputy Director
Winship Cancer Institute of Emory University
Emory University School of Medicine
Atlanta, Georgia



Mary Jo Fidler, MD

Associate Professor
Division of Hematology/Oncology
and Cell Therapy
Rush University
Chicago, Illinois



Lecia V. Sequist, MD, MPH

Landry Family Professor of Medicine
Harvard Medical School
Director of Center for Innovation
in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts



John V. Heymach, MD, PhD

Chair, Department of Thoracic/
Head and Neck Medical Oncology
David Bruton, Jr. Chair in Cancer Research
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas



Helena Yu, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York



Christine M. Lovly, MD, PhD

Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Program
Section Chief, Basic and Translational Research
Vanderbilt University Medical Center
Vanderbilt Ingram Cancer Center
Nashville, TN



2020 EGFR RESISTERS RESEARCH SUMMIT ATTENDEES



Joseph Chan, MD, PhD

Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
Uncovering Molecular Drivers of Neuroendocrine Plasticity in Patients with Small Cell Lung Cancer Transformation at Single-cell Level



Misako Nagasaka, MD

Assistant Professor
Karmanos Cancer Institute
Targeting HDAC6 to Overcome Osimertinib Resistance in the Treatment of EGFR-mutant NSCLC



Noura Choudhury, MD

Medical Oncology Fellow
Memorial Sloan Kettering Cancer Center
A Phase II Trial of Combination Amivantamab and Lazertinib in Metastatic EGFR-mutated Lung Adenocarcinoma with CNS Progression Using Integrated CSF cfDNA Analysis



Laura Petrillo, MD

Palliative Care Physician, Instructor of Medicine
Massachusetts General Hospital
Harvard Medical School
Patient-reported and End-of-Life Outcomes among Adults with Oncogene-driven Lung Cancer in a Palliative Care Clinical Trial



Fernando de Miguel, PhD

Postdoctoral Associate
Yale University
The Chromatin Remodeling Factor SMARCA4 Regulates Proliferation and Oxidative Stress in Osimertinib Resistant EGFR-mutant Lung Adenocarcinoma



Andrew Piper-Vallillo, MD

Fellow
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
High-dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-institutional Experience



Ines Pulido Endrino, PhD

Postdoctoral Research Associate
University of Illinois at Chicago
Endothelin-1-mediated Drug Resistance in EGFR-mutant NSCLC



Julia Rotow, MD

Clinical Instructor
Dana-Farber Cancer Institute
Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-small Cell Lung Cancer (NSCLC)



Lia Head, MD

Fellow Physician
Rush University Medical Center
Psychosocial Distress in Driver Mutant Lung Cancer Patients



Sherin Rouhani, MD, PhD

Hematology/Oncology Fellow
University of Chicago
The Neutrophil-to-Lymphocyte Ratio Is a Prognostic Biomarker in Patients with EGFR-mutated Advanced NSCLC



Sally Lau, MD

Clinical Research Fellow
Princess Margaret Cancer Centre
Subtypes of EGFR and HER2 Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors



Jaime Schneider, MD, PhD

Medical Oncology Fellow
Massachusetts General Hospital
Dana Farber Cancer Institute
Role of Metabolic Reprogramming in Mediating Resistance in Oncogene-driven Non-small Cell Lung Cancer



Kristen A. Marrone, MD

Assistant Professor
Johns Hopkins University School of Medicine
Harnessing EGFR-specific Immune Responses to Optimize Treatment



Manan P. Shah, MD

Internal Medicine Resident
Stanford University
EGFR Exon 20 Insertion NSCLC and Response to Platinum-based Chemotherapy



Catherine Meador, MD, PhD

Medical Oncology Clinical Fellow
Massachusetts General Hospital
Dana Farber Cancer Institute
Targeting EGFR Exon 20 Insertions: Recent Advances and Clinical Updates



Misha Cathien Tran, MD

Internal Medicine Resident
The University of Chicago
Concordance of Tissue and Cell-free DNA-based Next-generation Sequencing in Patients with Previously-treated Metastatic Non-small Cell Lung Cancer


2020 EGFR RESISTERS RESEARCH SUMMIT ATTENDEES



Hibiki Udagawa, MD, PhD
 Postdoctoral Fellow
 MD Anderson Cancer Center
EGFR Exon 20 Insertion Mutations in Non-small Cell Lung Cancer: Clinical Outcome from a Large-scale Clinico-genomic Database in the LC-SCRUM-Japan and Potential for TAS6417/CLN-081 as a Novel Therapeutic Strategy



Yunkai Zhang, PhD
 Research Fellow
 Vanderbilt University Medical Center
Identify, Characterize, and Develop Strategies to Combat Drug-tolerant Persister Cells (DTPCs) before the Development of Acquired TKI Resistance in EGFR-mutant Lung Cancer




Chao Wang, PhD
 Postdoctoral Fellow
 Moffitt Cancer Center
Exceptional Responders to Immunotherapy with EGFR Mutations




Yu "Michael" Zhou, MD
 Resident
 Rush University Medical Center
Impact of EGFR Mutational Status on Interfractional SBRT Lung Oligometastatic Tumor Response



Maya White, MD, MS
 Fellow
 Stanford University
Survival Outcomes in Lung Cancer Patients with Actionable Mutations Admitted to Intensive Care Units



2020 EGFR RESISTERS RESEARCH SUMMIT AT-A-GLANCE




MALE/FEMALE RATIO



Change in Attendee Confidence

Presentation Skills (out of 4.0)




"Truly wonderful, and quite exceptional to be able to translate the conference into a virtual format that remained engaging and personal."

"Amazingly connected despite the virtual nature."


Technology Made It Possible

"I like this virtual format. You can stay at home and communicate with experts, which is great!"

"Pre-sessions were very helpful to prepare for the meeting, and the logistics of this virtual summit have been incredible."




2020 EGFR RESISTERS RESEARCH SUMMIT EDUCATIONAL HIGHLIGHTS



Professional Skills Enhancement Workshop

In an effort to augment the professional development aspects of this program, CEC brought in our team of professional coaching experts from ListenWritePresent who have a long history of working with prospective and existing faculty in the medical and scientific space. Their team provided one-on-one coaching opportunities for each Young Investigator presenter prior to the launch of the meeting with sessions that included: presentation rehearsal, individualized coaching feedback on visual and verbal skills using video recording, and receipt of a personalized “Skill Builder” presentation at the end of the session.

2020 EGFR Resisters Research Summit attendees found the **ListenWritePresent Professional Skills Enhancement Workshop** to be an extremely valuable component of the EGFR Summit curriculum, ranking the coaching sessions with a mean score of **3.82** on a 4.0 scale.




What Participants Value Most

"This has been the most helpful meeting I have attended as a fellow. The opportunity to meet and network with such amazing faculty in a small group environment was awesome. The small group breakout sessions that gave us a chance to interact 1-on-1 with faculty were especially appreciated."

"Mentorship, squad debriefs, and networking."


"This was a very thoughtfully organized conference. I really appreciated the presentation coaching, care packages, and the dedication of the mentors to this activity, as well as the involvement of the advocates throughout. The best parts were small group interaction. It was tough not being in person, but this was the most engaged I have felt with a virtual conference during the pandemic, and I think that is because of how hard the organizers worked to make it work."



Mentoring Moments and Small-group Networking Sessions

"Great collegiality and approachability. The judge mentors are AWESOME!"

"Small groups with mentors were very useful."



2020 EGFR RESISTERS RESEARCH SUMMIT EDUCATIONAL HIGHLIGHTS



How Attending the Summit Will Impact Young Investigators' Careers

"Important researchers in the field are aware of who I am and the research I am doing."

"Perspective changing, inspiring, great exposure to other research in the EGFR+ landscape."

"Improved presentation skills and networking."

"Improving collaborations with other young investigators."

Unusual but Not Uninspiring!

"Fantastic job adapting this meeting to a virtual experience. The care packages beforehand were such a thoughtful touch. I really like that the meeting was small enough that we could get to know other participants and the faculty, and I like that everyone was encouraged to keep their video on for the entire meeting so you could 'see' everyone."

"Very well-organized conference that stands out from the rest. Really learned a lot. Enjoyed the balance of mentoring and research exposure. Especially the mentoring segments were great and can only say that even more of those segments could even be better!"



3rd Annual EGFR Resistors Research Summit

Watch for news on the 2021 EGFR Summit.

Follow us on Twitter @EGFRSummit or visit egfrsummit.com.

